Bill Text: TX HB2099 | 2019-2020 | 86th Legislature | Engrossed
Bill Title: Relating to modification of certain prescription drug benefits and coverage offered by certain health benefit plans.
Spectrum: Bipartisan Bill
Status: (Engrossed - Dead) 2019-05-15 - Co-sponsor authorized [HB2099 Detail]
Download: Texas-2019-HB2099-Engrossed.html
86R13008 SMT-F | ||
By: Lambert, Sheffield, Zerwas, Oliverson, | H.B. No. 2099 | |
Lucio III, et al. |
|
||
|
||
relating to modification of certain prescription drug benefits and | ||
coverage offered by certain health benefit plans. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Section 1369.0541, Insurance Code, is amended by | ||
amending Subsections (a) and (b) and adding Subsections (a-1) and | ||
(b-1) to read as follows: | ||
(a) Except as provided by Section 1369.055(a-1) and | ||
Subsection (b-1) of this section, a [ |
||
may modify drug coverage provided under a health benefit plan if: | ||
(1) the modification occurs at the time of coverage | ||
renewal; | ||
(2) the modification is effective uniformly among all | ||
group health benefit plan sponsors covered by identical or | ||
substantially identical health benefit plans or all individuals | ||
covered by identical or substantially identical individual health | ||
benefit plans, as applicable; and | ||
(3) not later than the 60th day before the date the | ||
modification is effective, the issuer provides written notice of | ||
the modification to the commissioner, each affected group health | ||
benefit plan sponsor, each affected enrollee in an affected group | ||
health benefit plan, and each affected individual health benefit | ||
plan holder. | ||
(a-1) The notice described by Subsection (a)(3) must | ||
include a statement: | ||
(1) indicating that the health benefit plan issuer is | ||
modifying drug coverage provided under the health benefit plan; | ||
(2) explaining the type of modification; and | ||
(3) indicating that, on renewal of the health benefit | ||
plan, the health benefit plan issuer may not modify an enrollee's | ||
contracted benefit level for any prescription drug that was | ||
approved or covered under the plan in the immediately preceding | ||
plan year as provided by Section 1369.055(a-1). | ||
(b) Modifications affecting drug coverage that require | ||
notice under Subsection (a) include: | ||
(1) removing a drug from a formulary; | ||
(2) adding a requirement that an enrollee receive | ||
prior authorization for a drug; | ||
(3) imposing or altering a quantity limit for a drug; | ||
(4) imposing a step-therapy restriction for a drug; | ||
[ |
||
(5) moving a drug to a higher cost-sharing tier; | ||
(6) increasing a coinsurance, copayment, deductible, | ||
or other out-of-pocket expense that an enrollee must pay for a drug; | ||
and | ||
(7) reducing the maximum drug coverage amount [ |
||
|
||
(b-1) Modifications affecting drug coverage that are more | ||
favorable to enrollees may be made at any time and do not require | ||
notice under Subsection (a), including: | ||
(1) the addition of a drug to a formulary; | ||
(2) the reduction of a coinsurance, copayment, | ||
deductible, or other out-of-pocket expense that an enrollee must | ||
pay for a drug; and | ||
(3) the removal of a utilization review requirement. | ||
SECTION 2. Section 1369.055, Insurance Code, is amended by | ||
adding Subsections (a-1), (a-2), and (c) to read as follows: | ||
(a-1) On renewal of a health benefit plan, the plan issuer | ||
may not modify an enrollee's contracted benefit level for any | ||
prescription drug that was approved or covered under the plan in the | ||
immediately preceding plan year and prescribed during that year for | ||
a medical condition or mental illness of the enrollee if: | ||
(1) the enrollee was covered by the health benefit | ||
plan on the date immediately preceding the renewal date; | ||
(2) a physician or other prescribing provider | ||
prescribes the drug for the medical condition or mental illness; | ||
and | ||
(3) the physician or other prescribing provider in | ||
consultation with the enrollee determines that the drug is the most | ||
appropriate course of treatment. | ||
(a-2) Modifications prohibited under Subsection (a-1) | ||
include: | ||
(1) removing a drug from a formulary; | ||
(2) adding a requirement that an enrollee receive | ||
prior authorization for a drug; | ||
(3) imposing or altering a quantity limit for a drug; | ||
(4) imposing a step-therapy restriction for a drug; | ||
(5) moving a drug to a higher cost-sharing tier; | ||
(6) increasing a coinsurance, copayment, deductible, | ||
or other out-of-pocket expense that an enrollee must pay for a drug; | ||
and | ||
(7) reducing the maximum drug coverage amount. | ||
(c) Subsections (a-1) and (a-2) do not: | ||
(1) prohibit a health benefit plan issuer from | ||
requiring, by contract, written policy or procedure, or other | ||
agreement or course of conduct, a pharmacist to provide a | ||
substitution for a prescription drug in accordance with Subchapter | ||
A, Chapter 562, Occupations Code, under which the pharmacist may | ||
substitute an interchangeable biologic product or therapeutically | ||
equivalent generic product as determined by the United States Food | ||
and Drug Administration; | ||
(2) prohibit a physician or other prescribing provider | ||
from prescribing another medication; | ||
(3) prohibit the health benefit plan issuer from | ||
adding a new drug to a formulary; | ||
(4) require a health benefit plan to provide coverage | ||
to an enrollee under circumstances not described by Subsection | ||
(a-1); or | ||
(5) prohibit a health benefit plan issuer from | ||
removing a drug from its formulary or denying an enrollee coverage | ||
for the drug if: | ||
(A) the United States Food and Drug | ||
Administration has issued a statement about the drug that calls | ||
into question the clinical safety of the drug; | ||
(B) the drug manufacturer has notified the United | ||
States Food and Drug Administration of a manufacturing | ||
discontinuance or potential discontinuance of the drug as required | ||
by Section 506C, Federal Food, Drug, and Cosmetic Act (21 U.S.C. | ||
Section 356c); or | ||
(C) the drug manufacturer has removed the drug | ||
from the market. | ||
SECTION 3. The changes in law made by this Act apply only to | ||
a health benefit plan that is delivered, issued for delivery, or | ||
renewed on or after January 1, 2020. A health benefit plan | ||
delivered, issued for delivery, or renewed before January 1, 2020, | ||
is governed by the law as it existed immediately before the | ||
effective date of this Act, and that law is continued in effect for | ||
that purpose. | ||
SECTION 4. This Act takes effect September 1, 2019. |